In this case, rheumatoid arthritis (RA) patients are treated with Tocilizumab, a competitive antagonist that targets the interaction between IL-6 and a soluble variant of its receptor IL-6R (sIL-6R, Figure 3B). Here, IL6 is linked to rheumatoid arthritis.